Using a combination of patient samples and cell lines of acute myeloid leukemia (AML), Floren et al. (2020) demonstrated that KAI1 contributed to the chemo-resistant type of AML; KAI1 overexpression was associated with significant reduction in cell death following chemotherapy (daunorubicin). Here, CD82 is linked to acute myeloid leukemia.